Can capmatinib be used in combination with osimertinib?

Capmatinib and Osimertinib (Osimertinib) are two targeted drugs commonly used in the treatment of non-small cell lung cancer (NSCLC), targeting MET mutations and EGFR mutations respectively. These two drugs are often used clinically to treat different types of mutations, so whether their combination is feasible needs to be evaluated on a patient-specific basis.

Capmatinib mainly targets non-small cell lung cancer with skip mutations in METexon14 and can effectively inhibit the growth of this mutated tumor. Osimertinib targets drug-resistant non-small cell lung cancer caused by EGFR mutations (especially T790M mutations) and can significantly improve the survival of patients. Although the two drugs have different mechanisms of action, they can work on different molecular targets. Sometimes doctors choose to use these two drugs in combination according to the patient's condition.

However, special attention must be paid to drug-drug interactions when capmatinib and osimertinib are used together. Although current research has not fully demonstrated the safety and efficacy of combining these two drugs, in theory, in certain circumstances, their combined treatment may have a broader suppressive effect in patients. For example, some patients may have both EGFR mutations and MET mutations, in which case combination therapy may be more effective in controlling tumor growth. However, combination therapy may also increase the risk of side effects, such as gastrointestinal upset, rash, and pulmonary complications.

Overall, the combined use of capmatinib and osimertinib still needs to be determined based on individualized treatment options. When patients choose combination therapy, they should fully discuss it with their oncologist, taking into account drug interactions, possible side effects, and the type of genetic mutations in their tumors. As more clinical data accumulates, more studies may support the combined use of these two drugs in the future, providing patients with more effective treatment options.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib